Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.34 |
| ▸ | ACACB | O00763 | 4/20 | 0.33 |
| ▸ | ACACA | Q13085 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.33 |
| ▸ | CKS1B | P61024 | 1/20 | 0.32 |
| ▸ | SKP1 | P63208 | 1/20 | 0.32 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | MAP3K5 | Q99683 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6711549 | 0.88 | KMT2A (0.35) | DRD2KMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL6711555 | 0.88 | KMT2A (0.35) | DRD2KMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL6712778 | 0.79 | ACACB (0.33) | DRD2KMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL6710611 | 0.74 | TK1 (0.38) | — | |
| SCHEMBL4859530 | 0.74 | TK1 (0.38) | — | |
| SCHEMBL4859526 | 0.74 | TK1 (0.38) | — | |
| SCHEMBL6710613 | 0.74 | TK1 (0.38) | — | |
| SCHEMBL4859519 | 0.74 | TK1 (0.38) | — | |
| SCHEMBL6711454 | 0.73 | KMT2A (0.33) | DRD2KMT2AL3MBTL1KDM1AMAOB | |
| SCHEMBL6711457 | 0.73 | KMT2A (0.33) | DRD2KMT2AL3MBTL1KDM1AMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040249152-A1 | Method for the production of cna | NANOGEN RECOGNOMICS GMBH (DE) | 2004-12-09 | — | — | US | claimed |
| US-20040249152-A1 | Method for the production of cna | NANOGEN RECOGNOMICS GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040249152-A1 | Method for the production of cna | RNGTT, COASY, CNOT7 | DRD2 4231/4885KMT2A 1942/4885L3MBTL1 830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.